Ikorel
(Nicorandil)Phase 3Small molecule
Merck & Co.Nicorandil is used to treat angina (chest pain caused by reduced blood flow to the heart). It helps relieve chest pain and improves the ability to exercise by widening blood vessels and reducing the heart's workload.[1] Ikorel is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Ikorel is one of 168 small molecule programs targeting Insulin resistance. It is currently in Phase 3.
9
Indications
27
Total Trials
5
Active Trials
167
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Ikorel
Merck & Co.Phase 3
Dexilant
TakedaPreclinical
Niclocide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Clomid
FerringPreclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Coronary Artery Disease2 trials
Efficacy2 trials
Myocardial Infarction2 trials
Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
Unknown status·—·Phase 4·NCT04826497·80 enrolled
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
Unknown status·—·Phase 4·NCT02435797·100 enrolled
Acute Myocardial Infarction2 trials
Treatment1 trial
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Active, not recruiting·—·Phase 2·NCT04120766·64 enrolled
17 more indications
Percutaneous Coronary Intervention1 trial
Chronic Stable Angina1 trial
Microvascular Dysfunction1 trial
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
Not yet recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06787430·170 enrolled
ST Elevation Myocardial Infarction1 trial
Prevention1 trial
Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Completed·—·Phase 1/2·NCT07138508·300 enrolled
Injury1 trial
Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury
Unknown status·TThe First Affiliated Hospital of Zhejiang Chinese Medical University·Phase 2·NCT05399576·150 enrolled
Chronic Total Occlusion1 trial
Percutaneous Coronary Intervention (PCI)1 trial
Heart Disease1 trial
Radiation Pneumonitis1 trial
Angina Pectoris1 trial
No-Reflow Phenomenon1 trial
Diabetes Mellitus, Type 21 trial
Coronary Artery Bypass Graft1 trial
Unspecified2 trials
China-Administration of Nicorandil Group（CHANGE）
Completed·—·Phase 4·NCT03445728·238 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicorandil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company